Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Amrein PC, Mims AS, Knight LW, Kelley D, Bottoms AS, Perry LH, Wahl JL, Brock J, Breton E, Marchione DM, Ho VT, Chen YB. Fathi AT, et al. Among authors: levis mj. Clin Cancer Res. 2023 Jun 1;29(11):2034-2042. doi: 10.1158/1078-0432.CCR-23-0182. Clin Cancer Res. 2023. PMID: 37014667 Clinical Trial.
Lestaurtinib: a multi-targeted FLT3 inhibitor.
Fathi AT, Levis M. Fathi AT, et al. Expert Rev Hematol. 2009 Feb;2(1):17-26. doi: 10.1586/17474086.2.1.17. Expert Rev Hematol. 2009. PMID: 21082990 Review.
FLT3 inhibitors: a story of the old and the new.
Fathi A, Levis M. Fathi A, et al. Curr Opin Hematol. 2011 Mar;18(2):71-6. doi: 10.1097/MOH.0b013e3283439a03. Curr Opin Hematol. 2011. PMID: 21245757 Free PMC article. Review.
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, Marmsater F, Robinson JE, Gross SD, Martinson M, Allen S, Kallan NC, Levis M. Fathi AT, et al. Leuk Res. 2012 Feb;36(2):224-31. doi: 10.1016/j.leukres.2011.07.011. Epub 2011 Jul 29. Leuk Res. 2012. PMID: 21802138 Free PMC article.
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH. Karp JE, et al. Among authors: levis mj. Clin Cancer Res. 2012 Dec 15;18(24):6723-31. doi: 10.1158/1078-0432.CCR-12-2442. Epub 2012 Oct 23. Clin Cancer Res. 2012. PMID: 23092873 Free PMC article. Clinical Trial.
FLT3 inhibitor-induced neutrophilic dermatosis.
Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB. Fathi AT, et al. Blood. 2013 Jul 11;122(2):239-42. doi: 10.1182/blood-2013-01-478172. Epub 2013 May 17. Blood. 2013. PMID: 23687091 Free article.
Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.
Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS. Goswami M, et al. Among authors: levis mj. Leukemia. 2014 May;28(5):1167-70. doi: 10.1038/leu.2014.14. Epub 2014 Jan 10. Leukemia. 2014. PMID: 24472813 Free PMC article. No abstract available.
215 results